Dynavax Technologies (NASDAQ:DVAX) Earns “Buy” Rating from HC Wainwright

Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $29.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 138.68% from the company’s previous close.

Separately, The Goldman Sachs Group reduced their price target on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th.

Dynavax Technologies Stock Up 1.1 %

Shares of NASDAQ DVAX opened at $12.15 on Friday. Dynavax Technologies has a 1 year low of $9.74 and a 1 year high of $15.01. The firm’s 50-day moving average is $11.13 and its 200-day moving average is $11.24. The company has a current ratio of 14.18, a quick ratio of 13.18 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $1.59 billion, a PE ratio of 109.28 and a beta of 1.34.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. The firm had revenue of $73.80 million for the quarter, compared to analysts’ expectations of $76.92 million. During the same period last year, the firm earned $0.03 earnings per share. Equities analysts expect that Dynavax Technologies will post 0.16 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Texas Permanent School Fund Corp increased its position in shares of Dynavax Technologies by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 113,128 shares of the biopharmaceutical company’s stock valued at $1,404,000 after buying an additional 1,467 shares in the last quarter. Duality Advisers LP acquired a new stake in shares of Dynavax Technologies during the first quarter worth about $227,000. ClariVest Asset Management LLC lifted its holdings in shares of Dynavax Technologies by 11.5% during the 1st quarter. ClariVest Asset Management LLC now owns 108,752 shares of the biopharmaceutical company’s stock valued at $1,350,000 after purchasing an additional 11,235 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Dynavax Technologies by 8.3% in the 1st quarter. ProShare Advisors LLC now owns 35,269 shares of the biopharmaceutical company’s stock valued at $438,000 after purchasing an additional 2,691 shares during the period. Finally, Mizuho Markets Americas LLC increased its stake in Dynavax Technologies by 16.9% during the 1st quarter. Mizuho Markets Americas LLC now owns 852,057 shares of the biopharmaceutical company’s stock worth $10,574,000 after purchasing an additional 123,300 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.